Over the two and a half days of AMS, attendees have heard that additive manufacturing is part of a broader advanced manufacturing value chain, which is both complex and rapidly growing. With tremendous opportunities to invest in the industry, how does one make informed decisions without getting caught up in the hype cycle?
During this final, interactive AMS session, experts from The Barnes Global Advisors (TBGA) will provide a baseline approach to communicating the value of AM. Using TBGA’s industry-leading tools, investors and those seeking investments will learn how to assess the value of a company and its technology. From the Simplified View of AM to the TBGA AM Maturity Model, TBGA ADDvisors® will show how to assess where a company fits in the value chain and how growth-oriented and viable it is for future investment.
Participants will receive a quick reference guide with key questions and information to guide future conversations as well as a digital badge indicating completion of The Barnes Global Advisors Economics of Additive training.
Who should attend: Professionals making investment decisions in advanced and additive manufacturing who seek to increase their understanding of AM technology, markets, and value to inform investment decisions. AM Business leaders who want to know how best to frame conversations with investors from a technology, market, and value standpoint.
*Full AMS registrants receive automatic access to this workshop. You can also opt to register for the workshop only by selecting the appropriate choice on the AMS registration page.
AMS will return to NYC on Feb 4-6, 2025. Early bird registration will open soon. Click here to join the mailing list.
AMS will return to NYC on Feb 4-6, 2025. Early bird registration will open soon. Click here to join the mailing list.
Dr. Stephanie Willerth – a Full Professor and Canada Research Chair in Biomedical Engineering at the University of Victoria – runs an internationally recognized and award winning research group that specializes in bioprinting complex human tissue models. She also serves as the C.E.O. of Axolotl Biosciences – a spin off biotechnology company focused on developing superior quality reagents for 3D printing human tissue models, making research and drug discovery easier than ever.
